PMID- 36105007
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220917
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 14
IP  - 8
DP  - 2022
TI  - The promising significance of liraglutide combined with dapagliflozin or 
      empagliflozin in the prevention of early diabetic nephropathy.
PG  - 5622-5629
AB  - OBJECTIVE: To explore the significance of liraglutide combined with dapagliflozin 
      or empagliflozin in the prevention of early diabetic nephropathy (DN) and its 
      effects on renal function indices. METHODS: Three hundred patients with type 2 
      diabetes mellitus (T2DM) treated in our hospital from April 2019 to April 2020 
      were retrospectively included and divided into two groups according to different 
      treatment regimens. Among them, 150 patients who received liraglutide alone were 
      included in the single-drug group, and 150 patients treated with liraglutide 
      combined with dapagliflozin or empagliflozin were included in the combination 
      group. The baseline data and the improvement of inflammatory indices, blood 
      glucose indices and renal function-related indices were compared between the two 
      groups of patients. RESULTS: The baseline data such as age, body mass index, 
      retinopathy, and course of disease had no significant difference between the two 
      groups (P > 0.05). After treatment, the waist-to-hip ratio, total body fat 
      percentage, total body fat mass, total body lean mass, and A/G ratio were 
      significantly decreased in both groups (P < 0.05) compared with before treatment, 
      and were significantly lower in the combination group than in the single-drug 
      group (P < 0.05). The combination group had significantly lower urinary 
      transferrin (Tf), neutrophil gelatinase-associated lipocalin (NGAL) and tumor 
      necrosis factor (TNF)-alpha, insulin-like growth factor 1 (IGF-1), retinol-binding 
      protein (RBP), homocysteine (Hcy), brain natriuretic peptide (BNP), 24 h urinary 
      albumin excretion ratio (UAER), urine albumin to creatinine ratio (UACR) and 
      urinary liver-type fatty acid binding protein (L-FABP) levels, and higher 
      secretory frizzled-related protein 5 levels than the single-drug group after 
      treatment (P < 0.05). CONCLUSION: Liraglutide combined with dapagliflozin or 
      empagliflozin treatment can effectively reduce the levels of Tf, NGAL and TNF-alpha 
      in patients with T2DM, and improve the renal function in terms of IGF-1, RBP, 
      Hcy, BNP, UAER, UACR, L-FABP, showing high treatment safety.
CI  - AJTR Copyright (c) 2022.
FAU - Li, Qin
AU  - Li Q
AD  - Department of Endocrinology, General Hospital of The Yangtze River Shipping Wuhan 
      430010, Hubei Province, China.
FAU - Wang, Xing
AU  - Wang X
AD  - Department of Endocrinology, Shanghai Pudong New Area Gongli Hospital Shanghai 
      200135, China.
FAU - Guo, Aili
AU  - Guo A
AD  - Department of Endocrinology, General Hospital of The Yangtze River Shipping Wuhan 
      430010, Hubei Province, China.
FAU - Zheng, Wenxia
AU  - Zheng W
AD  - Department of Endocrinology, General Hospital of The Yangtze River Shipping Wuhan 
      430010, Hubei Province, China.
FAU - Bi, Jin
AU  - Bi J
AD  - Department of Endocrinology, General Hospital of The Yangtze River Shipping Wuhan 
      430010, Hubei Province, China.
FAU - He, Yan
AU  - He Y
AD  - Department of Endocrinology, General Hospital of The Yangtze River Shipping Wuhan 
      430010, Hubei Province, China.
FAU - Luo, Qiong
AU  - Luo Q
AD  - Department of Endocrinology, General Hospital of The Yangtze River Shipping Wuhan 
      430010, Hubei Province, China.
LA  - eng
PT  - Journal Article
DEP - 20220815
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC9452308
OTO - NOTNLM
OT  - Diabetic nephropathy
OT  - dapagliflozin
OT  - early lesions
OT  - liraglutide
OT  - renal function
COIS- None.
EDAT- 2022/09/16 06:00
MHDA- 2022/09/16 06:01
PMCR- 2022/08/15
CRDT- 2022/09/15 02:14
PHST- 2022/02/18 00:00 [received]
PHST- 2022/07/05 00:00 [accepted]
PHST- 2022/09/15 02:14 [entrez]
PHST- 2022/09/16 06:00 [pubmed]
PHST- 2022/09/16 06:01 [medline]
PHST- 2022/08/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2022 Aug 15;14(8):5622-5629. eCollection 2022.